PTG-300
PTG-300-03
Phase 2 small_molecule completed
Quick answer
PTG-300 for β-thalassemia is a Phase 2 program (small_molecule) at Protagonist Therapeutics, Inc with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Protagonist Therapeutics, Inc
- Indication
- β-thalassemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed